studi
humanspecif
infecti
agent
hinder
lack
optim
small
anim
model
recent
develop
novel
strain
immunodefici
mice
begun
provid
opportun
util
small
anim
model
studi
mani
humanspecif
infecti
agent
introduct
target
mutat
receptor
common
gamma
chain
gene
null
mice
alreadi
defici
b
cell
led
breakthrough
abil
engraft
hematopoiet
stem
cell
well
function
human
lymphoid
cell
tissu
effect
creat
human
immun
system
immunodefici
mice
human
mice
becom
increasingli
import
preclin
model
studi
human
immunodefici
humanspecif
infecti
agent
howev
remain
number
opportun
improv
human
mous
model
studi
humanspecif
infecti
agent
done
implement
innov
technolog
collect
acceler
develop
new
model
genet
modifi
mice
includ
modif
host
reduc
innat
immun
imped
human
cell
engraft
ii
genet
modif
provid
humanspecif
growth
factor
cytokin
requir
optim
human
cell
growth
function
iii
new
cell
tissu
engraft
protocol
develop
next
gener
human
mous
model
continu
provid
excit
opportun
establish
robust
small
anim
model
studi
pathogenesi
humanspecif
infecti
agent
well
test
efficaci
therapeut
agent
experiment
vaccin
number
humanspecif
infecti
agent
small
anim
model
critic
need
permit
effici
costeffect
evalu
diseas
pathogenesi
therapeut
respons
vivo
develop
new
vaccin
without
put
individu
risk
sinc
mani
agent
infect
human
cell
tissu
baumler
fang
wolf
et
al
tradit
small
anim
model
mice
rat
use
host
infect
addit
humanspecif
natur
mani
infecti
agent
also
cell
tissuespecif
requir
infect
baumler
fang
wolf
et
al
exampl
neiserria
gonorrhoea
infect
human
epitheli
cell
due
requir
bind
human
glycoprotein
enter
cell
protein
differ
human
speci
voge
et
al
thu
develop
new
small
anim
model
studi
humanspecif
cell
tissuespecif
agent
requir
engraft
anim
multipl
type
human
cell
tissu
includ
human
hematopoiet
immun
system
develop
next
gener
human
mice
acceler
investig
current
known
humanspecif
infecti
agent
includ
exampl
human
immunodefici
viru
type
support
rapid
identif
studi
new
emerg
humanspecif
infecti
agent
exampl
middl
east
respiratori
syndrom
coronaviru
merscov
http
wwwwhointcsrdon
engraft
function
human
immun
system
immunodefici
mice
three
major
model
system
describ
commonli
use
protocol
establish
model
review
recent
rongvaux
et
al
ito
et
al
model
system
strength
limit
studi
human
immunobiolog
limit
provid
fresh
opportun
improv
model
studi
human
infecti
diseas
evalu
vaccin
simplest
approach
engraft
human
immun
system
inject
human
peripher
blood
lymphocyt
pbl
adult
immunodefici
mice
term
hupblscid
model
mosier
et
al
system
pbl
inject
intraperiton
intraven
nonirradi
condit
usual
sublethallyirradi
condit
recipi
primari
popul
engraft
cell
cell
mosier
et
al
king
et
al
ito
et
al
introduc
cell
rapidli
acquir
activ
phenotyp
one
week
b
cell
myeloid
cell
immun
cell
detect
ito
et
al
king
et
al
model
use
studi
effector
cell
activ
result
hupblscid
mice
shown
capabl
mediat
human
skin
islet
allograft
reject
king
et
al
racki
et
al
howev
model
limit
window
experiment
observ
rel
short
engraft
mice
develop
lethal
xenogen
graftversushost
diseas
gvhd
within
week
ito
et
al
king
et
al
second
model
known
husrcscid
establish
inject
human
hematopoiet
stem
cell
hsc
defin
function
scidrepopul
cell
src
newborn
adult
immunodefici
recipi
lapidot
et
al
human
hsc
usual
obtain
bone
marrow
umbil
cord
blood
granulocytecoloni
stimul
factor
gcsf
mobil
peripher
blood
fetal
liver
fetal
liver
cord
blood
commonli
use
sourc
effici
repopul
immunodefici
mice
adult
hsc
matsumura
et
al
lepu
et
al
husrcscid
model
complet
human
hematopoiet
immun
system
develop
howev
human
cell
undergo
thymic
educ
posit
neg
select
mous
thymu
mous
mhc
restrict
preclud
appropri
hlarestrict
interact
human
antigenpres
cell
apc
human
cell
peripher
tissu
watanab
et
al
husrcscid
model
use
extens
studi
human
hematopoiesi
cellmedi
immun
well
infecti
diseas
hiv
epsteinbarr
viru
ebv
rongvaux
et
al
ito
et
al
third
model
system
overcom
challeng
seen
establish
subren
capsul
transplant
fragment
human
fetal
liver
thymu
adult
immunodefici
mice
accompani
intraven
inject
autolog
hsc
fetal
liver
term
bone
marrowliverthymu
blt
model
lan
et
al
melku
et
al
engraft
mice
use
blt
model
allow
develop
complet
human
hematopoiet
immun
system
develop
human
cell
educ
human
thymu
hlarestrict
rongvaux
et
al
shultz
et
al
three
model
blt
model
system
provid
robust
human
immun
system
engraft
becom
model
system
choic
studi
infecti
agent
target
human
hematopoiet
immun
system
blt
mice
also
develop
human
mucos
immun
system
permit
studi
mucos
immun
follow
exampl
hiv
infect
via
oral
vagin
rectal
rout
chateau
et
al
ml
chateau
et
al
caveat
blt
model
eventu
develop
wast
syndrom
resembl
gvhd
report
mani
greenblatt
et
al
lockridg
et
al
covassin
et
al
ali
et
al
ono
et
al
laboratori
one
report
hsc
allogen
thymu
inject
along
remov
preexist
matur
cell
gvhd
observ
kalscheuer
et
al
variabl
gvhd
develop
among
differ
research
group
may
due
vari
level
matur
cell
inoculum
coloni
variabl
exampl
variabl
microbiom
flora
antibiot
administr
exposur
variabl
bed
mechan
underli
develop
wast
syndrom
remain
open
question
base
observ
hupblscid
model
gvhd
king
et
al
may
due
loss
toler
human
immun
system
murin
mhc
antigen
three
major
advanc
develop
small
anim
model
engraft
function
human
cell
tissu
immun
system
first
discoveri
immunodefici
scid
mous
bosma
et
al
provid
foundat
subsequ
descript
human
hematopoiet
immun
cell
engraft
mosier
et
al
mccune
et
al
report
soon
led
establish
first
small
anim
model
studi
hiv
infect
mosier
et
al
howev
low
level
human
hematopoiet
immun
cell
engraft
could
establish
mice
sever
limit
util
subsequ
develop
nodscid
mice
shultz
et
al
koyanagi
et
al
permit
much
higher
level
human
hematopoiet
immun
cell
engraft
howev
complet
restor
human
immun
system
develop
human
cell
hsc
achiev
rongvaux
et
al
ito
et
al
breakthrough
field
came
develop
immunodefici
scid
null
null
mice
earli
bear
target
mutat
receptor
common
gamma
chain
null
ito
et
al
shultz
et
al
traggiai
et
al
common
gamma
chain
requir
highaffin
signal
cytokin
receptor
rochman
et
al
block
highaffin
signal
receptor
sever
dampen
innat
immun
promot
heighten
engraft
function
human
cell
null
immunodefici
mice
show
multipl
defici
innat
immun
complet
lack
natur
killer
nk
cell
requir
develop
function
ito
et
al
shultz
et
al
traggiai
et
al
nk
cell
one
primari
host
innat
immun
factor
hinder
human
cell
engraft
shultz
et
al
importantli
nodscid
null
mice
develop
mous
thymic
lymphoma
kato
et
al
depend
achiev
normal
life
span
approach
year
contrast
nodscid
mice
rel
short
lifespan
due
develop
thymic
lymphoma
begin
die
start
month
age
shultz
et
al
although
immunodefici
mice
bear
null
gene
permit
first
time
establish
human
mice
bear
complet
human
immun
system
follow
engraft
human
hsc
found
nk
cell
defici
sole
factor
regul
engraft
deplet
nk
cell
nodscid
mice
follow
treatment
monoclon
antibodi
surprisingli
lead
high
level
human
engraft
level
immun
function
attain
immunodefici
null
mice
christianson
et
al
shultz
et
al
although
report
suggest
blt
model
similar
engraft
level
observ
nodscid
nsg
mice
brainard
et
al
report
continu
demonstr
superior
engraft
nsg
mice
compar
nodscid
mice
model
stoddart
et
al
reason
observ
differ
understood
three
major
strain
immunodefici
null
mice
commonli
use
investig
nodcgprkdc
scid
abbrevi
nodscid
null
nsg
ishikawa
et
al
nodcgprkdc
scid
nog
ito
et
al
yahata
et
al
cg
abbrevi
null
null
brg
mice
traggiai
et
al
origin
similar
differ
three
strain
immunodefici
null
mice
extens
review
strain
advantag
disadvantag
depend
upon
engraft
model
system
use
establish
human
mice
shultz
et
al
rongvaux
et
al
ito
et
al
develop
immunodefici
null
mice
import
studi
regen
medicin
immun
hematopoiesi
cancer
infecti
diseas
rongvaux
et
al
ito
et
al
howev
mani
opportun
improv
model
studi
infecti
agent
exampl
studi
human
immun
opportun
includ
enhanc
human
primari
recal
humor
immun
respons
promot
effici
class
switch
immunoglobulin
g
antibodi
product
gener
memori
cell
opportun
also
includ
improv
format
lymphoid
structur
develop
germin
center
current
poorli
develop
immunodefici
null
mice
lack
express
lead
decreas
mous
lymphoid
tissu
induc
lti
cell
well
poorli
develop
lymph
node
discoveri
approach
increas
number
function
lti
cell
lead
enhanc
lymph
node
structur
improv
immun
respons
addit
futur
direct
includ
provis
humanspecif
growth
factor
cytokin
requir
optim
human
cell
engraft
function
within
model
anim
rongvaux
et
al
ito
et
al
new
techniqu
engraft
human
cell
tissu
human
hepatocyt
develop
establish
optim
studi
infecti
agent
plasmodium
falciparum
infect
hepatocyt
part
life
cycl
vaughan
et
al
final
recent
develop
novel
technolog
permit
rapid
genet
modif
mice
acceler
gener
new
model
immunodefici
null
mice
need
capit
discoveri
new
approach
enhanc
engraft
function
human
tissu
see
overal
improv
human
mous
model
encompass
reduct
murin
host
innat
immun
simultan
enhanc
human
innat
adapt
immun
reduc
develop
xenogen
gvhd
although
introduct
null
gene
scid
null
null
background
sever
crippl
host
innat
immun
therebi
enhanc
human
cell
engraft
function
number
remain
host
innat
immun
factor
still
need
manipul
order
achiev
optim
human
cell
engraft
furthermor
model
human
immun
system
engraft
particularli
hupblscid
model
develop
lethal
xenogen
gvhd
limit
longterm
studi
need
address
ito
et
al
king
et
al
one
major
factor
regul
human
cell
engraft
immunodefici
null
strain
signal
regulatori
protein
alpha
sirpa
receptorligand
interact
sirpa
highli
express
macrophag
dendrit
cell
neutrophil
cell
innat
immun
system
phagocyt
activ
function
clear
infecti
agent
dead
die
cell
foreign
cell
includ
xenogen
human
cell
transplant
murin
recipi
tsai
discher
matozaki
et
al
barclay
brown
ligand
sirpa
ubiquit
express
almost
cell
bodi
includ
hematopoiet
lymphoid
cell
yamauchi
et
al
appropri
signal
complex
provid
neg
regulatori
signal
phagocyt
cell
essenc
eat
signal
signal
complex
critic
regul
engraft
human
cell
immunodefici
null
mice
yamauchi
et
al
takenaka
et
al
nsg
mice
nod
strainderiv
polymorph
sirpa
close
resembl
human
sirpa
permit
appropri
recognit
human
hematopoiet
cell
enhanc
engraft
effici
takenaka
et
al
contrast
balbc
mice
sirpa
polymorph
close
relat
human
sirpa
imped
appropri
signal
sirpa
receptor
limit
human
hematopoiet
cell
engraft
due
ineffect
neg
regulatori
signal
host
innat
immun
cell
yamauchi
et
al
transgen
express
human
sirpa
brg
strowig
et
al
nod
sirpa
null
yamauchi
et
al
mice
increas
human
hematopoiet
cell
engraft
yamauchi
et
al
moreov
balbc
mice
intact
hemolyt
complement
permit
studi
involv
complement
cascad
immun
respons
complement
activ
readili
detect
vivo
yamauchi
et
al
contrast
immunodefici
null
strain
base
nod
background
lack
hemolyt
complement
due
delet
code
region
hemolyt
complement
hc
gene
encod
complement
compon
shultz
et
al
mutat
prevent
format
membran
attack
complex
address
recent
backcross
intact
hc
gene
cbaj
strain
gener
nsg
mice
intact
complement
system
ld
unpublish
data
moreov
recent
report
null
null
null
mice
also
elev
human
hematopoiet
cell
engraft
level
blt
model
system
lavend
et
al
null
null
null
mice
addit
intact
complement
system
also
appear
develop
appropri
lymphoidlik
structur
blt
model
contrast
observ
nsg
nog
mice
greenblatt
et
al
lockridg
et
al
covassin
et
al
ali
et
al
null
null
null
mice
show
sign
wast
gvhdlike
syndrom
week
engraft
lavend
et
al
laboratori
current
develop
nsgtg
sirpa
mice
well
tg
mice
determin
whether
genet
modif
pathway
enhanc
develop
lymphoid
structur
reduc
develop
xenogen
gvhd
blt
model
extend
observ
support
import
pathway
cell
type
hematopoiet
cell
also
shown
intrasplen
inject
human
hepatocyt
transduc
express
murin
increas
human
hepatocyt
engraft
balbctg
mice
waern
et
al
altern
approach
potenti
reduc
develop
xenogvhd
elimin
murin
target
human
xenogvhd
respons
use
vitro
xenomix
lymphocyt
reaction
determin
major
compon
xenogen
respons
direct
murin
mhc
class
class
ii
molecul
king
et
al
furthermor
xenogvhd
delay
hupblscid
model
nsg
class
class
ii
defici
recipi
use
recipi
king
et
al
determin
whether
human
cell
xenoreact
predomin
direct
murin
mhc
class
ii
inject
purifi
human
cell
nsg
mhc
class
ii
knockout
mice
model
system
develop
xenogvhd
significantli
delay
suggest
xenogvhd
respons
human
cell
predomin
direct
murin
mhc
class
ii
loci
covassin
et
al
similar
result
obtain
enrich
human
cell
inject
nsg
class
defici
recipi
mab
unpublish
data
howev
nsg
mhc
class
nsg
mhc
class
ii
defici
mice
use
blt
model
littl
delay
develop
wast
syndrom
observ
covassin
et
al
investig
role
murin
mhc
class
class
ii
develop
xenogvhd
hupblscid
model
wast
syndrom
nsgblt
model
gener
nsg
mice
defici
mhc
class
class
ii
use
two
approach
first
cross
nsg
microglobulin
knockout
mice
nsg
mice
defici
mhc
class
ii
ia
locu
howev
hand
nsg
mice
defici
microglobulin
exhibit
poor
breed
characterist
address
issu
also
gener
nsg
class
iii
knockout
mice
use
second
approach
nodcgprkdc
scid
sz
abbrevi
nsg
k
b
b
null
mice
express
murin
mhc
class
molecul
excel
breeder
use
talen
technolog
rapidli
target
disrupt
murin
iab
mhc
class
ii
allel
nsg
k
b
b
null
mice
gaj
et
al
addit
approach
prevent
reduc
elimin
human
cell
host
macrophag
includ
restrict
phagocyt
abil
elimin
host
use
liposomeencapsul
clodron
liposom
kill
macrophag
vivo
use
increas
engraft
surviv
human
rbc
macrophag
normal
remov
rapidli
circul
hu
et
al
howev
treatment
toxic
given
long
term
also
toxic
engraft
human
macrophag
address
current
develop
number
nsg
model
permit
reduct
host
macrophag
exampl
analyz
nsg
mice
express
diphtheria
toxin
receptor
control
promot
specif
delet
murin
myeloid
dendrit
cell
popul
would
permit
interact
infecti
agent
human
macrophag
popul
without
confound
effect
activ
due
murin
host
macrophag
anoth
host
factor
complic
studi
innat
immun
respons
infecti
agent
murin
express
tolllik
receptor
tlr
host
cell
almost
infecti
agent
pathogenassoci
molecular
pattern
pamp
react
pattern
recognit
receptor
prr
host
innat
immun
cell
includ
prr
tlr
famili
kawai
akira
hoeb
et
al
furthermor
tlr
receptor
differ
mice
human
mice
express
present
human
savva
roger
thu
studi
innat
immun
respons
human
myeloid
cell
infecti
agent
confound
correspond
innat
immun
respons
host
myeloid
cell
address
gener
nsg
mice
defici
cytosol
adapt
protein
type
interferon
ifn
receptor
also
develop
nsg
mice
defici
neutrophil
cytosol
factor
cross
nsg
mice
mice
thayer
et
al
gene
control
superoxid
product
macrophag
neutrophil
respons
much
cytotox
activ
nauseef
number
speciesspecif
factor
import
cell
develop
function
differ
mous
human
mani
describ
recent
review
rongvaux
et
al
ito
et
al
number
technic
approach
use
either
suppli
knockout
knockin
factor
target
mous
host
gene
encod
factor
interfer
human
cell
engraft
function
fig
one
opportun
gener
immun
system
engraft
human
mice
enhanc
develop
function
human
innat
immun
cell
exampl
human
myeloid
cell
found
circul
human
hsc
engraft
nsg
mice
myeloid
cell
present
phenotyp
immatur
exhibit
function
impair
gill
et
al
begin
address
investig
administr
recombin
human
gcsf
increas
human
myeloid
cell
circul
includ
granulocyt
macrophag
rare
observ
blood
human
hscengraft
mice
rathinam
et
al
transgen
mice
express
human
granulocytemonocytecoloni
stimul
factor
gmcsf
also
show
enhanc
human
myeloid
cell
level
circul
anoth
approach
introduc
mice
hydrodynam
shock
express
plasmid
contain
gmcsf
lead
increas
number
human
dendrit
cell
chen
et
al
next
gener
model
human
mice
provid
factor
import
human
myeloid
granulocyt
dendrit
cell
develop
improv
human
innat
immun
enhanc
human
adapt
immun
number
approach
use
first
challeng
mani
cytokin
need
develop
function
human
immun
cell
speciesspecif
human
cytokin
need
provid
optim
immun
system
develop
review
see
rongvaux
et
al
ito
et
al
describ
recent
review
great
progress
provid
factor
immunodefici
null
nsg
nog
brg
mice
particular
interest
center
provid
factor
enhanc
human
hematopoiesi
human
stem
cell
factor
takagi
et
al
thrombopoietin
import
develop
function
human
hematopoiet
immun
system
note
one
opportun
improv
human
immun
cell
engraft
immunodefici
null
mice
enhanc
abil
engraft
immun
system
mount
primari
secondari
immun
respons
follow
immun
sporad
report
suggest
antibodi
class
switch
immun
respons
igm
product
igg
product
affin
matur
occur
primarili
report
mice
transgen
express
human
hla
class
ii
molecul
danner
et
al
suzuki
et
al
human
b
cell
hscengraft
human
mice
immatur
transit
phenotyp
express
high
level
contrast
normal
observ
human
biswa
et
al
matsumura
et
al
watanab
et
al
approach
enhanc
b
cell
differenti
function
includ
provis
factor
recombin
bli
baff
howev
nsg
transgen
express
human
bli
show
enhanc
human
b
cell
function
ld
mab
unpublish
observ
differ
observ
may
due
high
level
mous
bli
immunodefici
mice
bind
human
bli
receptor
signal
follow
bind
essenc
becom
decoy
molecul
block
human
bli
signal
human
b
cell
inabl
transgen
express
human
bli
support
human
b
cell
develop
surviv
investig
genet
cross
nsg
bli
knockout
mice
addit
opportun
focu
improv
organ
lymphoid
structur
germin
center
human
immunodefici
null
mice
lack
wellorgan
lymphoid
tissu
rongvaux
et
al
ito
et
al
lymphoid
tissu
induc
lti
cell
member
emerg
famili
innat
lymphoid
cell
ilc
crucial
lymph
node
develop
lti
cell
hematopoiet
deriv
cell
eberl
et
al
absent
immunodefici
null
mice
due
lack
signal
receptor
role
activ
mesenchym
cell
lymph
node
peyer
patch
appear
mediat
express
membranebound
yoshida
et
al
mebiu
et
al
bind
express
mesenchym
cell
honda
et
al
approach
activ
mesenchym
cell
receptor
absenc
lti
cell
may
altern
approach
induc
develop
lymph
node
anlagen
immunodefici
null
mice
howev
simpl
induct
lymph
node
anlagen
may
suffici
develop
desir
structur
compon
lymph
node
splenic
germin
center
human
mice
second
popul
import
format
structur
mainten
lymph
node
spleen
germin
center
follicular
dendrit
cell
fdc
aguzzi
et
al
cell
stromal
origin
krautler
et
al
immunodefici
null
mice
engraft
hsc
fdc
mous
origin
cell
requir
bridg
innat
adapt
b
cell
immun
respons
stimul
via
tlr
aguzzi
et
al
fdc
requir
b
cell
provis
tumor
necrosi
factor
tnf
lymphotoxin
lt
develop
mainten
mackay
et
al
allen
cyster
ware
current
known
whether
predominantli
human
b
cell
popul
gener
human
mice
follow
hsc
engraft
provid
help
fdc
also
import
role
recruit
follicular
helper
cell
altern
approach
enhanc
fdc
develop
mainten
human
mice
opportun
optim
adapt
immun
respons
engraft
human
immun
system
mhc
molecul
requir
normal
cell
develop
function
also
appropri
interact
antigenpres
cell
involv
gener
adapt
immun
respons
human
mhc
complex
term
hla
number
immunodefici
null
hla
transgen
mice
gener
almost
hla
transgen
mice
gener
exclus
nsg
strain
nog
strain
hla
class
major
experiment
effort
focus
molecul
caucasian
north
america
express
hla
class
molecul
review
see
rongvaux
et
al
ito
et
al
publish
work
use
transgen
mice
husrcscid
model
shown
human
cell
develop
restrict
respons
ebv
infect
strowig
et
al
number
hlaclass
ii
transgen
human
mice
also
gener
tmmom
transgen
mice
engraft
hsc
appear
exhibit
increas
antibodi
respons
danner
et
al
suzuki
et
al
cross
nsg
mice
express
human
hla
class
class
ii
nsg
murin
mhc
class
iii
knockout
mice
gener
permit
develop
human
cell
nsg
recipi
restrict
exclus
appropri
hla
infecti
agent
interest
includ
bacteri
viral
protozoan
agent
model
studi
agent
highli
depend
human
cell
tissu
requir
cell
entri
replic
pathogenesi
specif
infecti
agent
wolf
et
al
baumler
fang
exampl
human
known
reservoir
salmonella
enterica
serovar
typhi
salmonella
typhi
seland
et
al
recent
two
report
use
immunodefici
mice
engraft
hsc
develop
model
typhi
libbi
et
al
song
et
al
one
model
base
nsg
mice
libbi
et
al
infect
typhi
lead
progress
lethal
infect
libbi
et
al
contrast
infect
hsc
engraft
brg
mice
although
lead
high
organ
level
appear
lethal
observ
hscengraft
nsg
mice
song
et
al
illustr
two
import
point
first
human
mice
use
studi
pathogenesi
humanspecif
infecti
agent
typhi
second
subtl
import
genet
differ
exist
model
system
depend
question
address
one
system
may
better
suit
experiment
use
number
humanspecif
infecti
agent
studi
small
anim
model
due
avail
human
mice
includ
hepat
virus
hiv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
dengu
viru
neiserria
gonorrhoea
neisseria
meningitid
measl
viru
p
falciparum
review
see
rongvaux
et
al
ito
et
al
brehm
et
al
b
ikeno
et
al
howev
human
mous
model
use
studi
infecti
agent
like
depend
tissu
tropism
approach
engraft
variou
human
tissu
human
mice
critic
fig
exampl
human
mous
model
engraft
human
immun
system
develop
hiv
infect
cell
lymphoid
system
cell
macrophag
brehm
et
al
b
hepat
virus
requir
human
hepatocyt
target
cell
approach
engraft
human
hepatocyt
immunodefici
mice
genet
modifi
enhanc
xenogen
human
hepatocyt
engraft
develop
washburn
et
al
dandri
et
al
kosaka
et
al
azuma
et
al
brezillon
et
al
lutgehetmann
et
al
mercer
et
al
brown
et
al
morosan
et
al
bissig
et
al
vaughan
et
al
recent
report
human
mice
engraft
human
hepatocyt
human
hsc
donor
permit
model
system
hepat
viru
infect
studi
liver
presenc
autolog
human
immun
system
biliti
et
al
infecti
organ
p
falciparum
human
liver
circul
human
rbc
requir
complet
life
cycl
occur
tuteja
human
rbc
present
low
level
circul
hscengraft
nsg
mice
larg
part
due
remov
host
macrophag
hu
et
al
mention
genet
modif
host
develop
diminish
mous
macrophag
activ
hscengraft
human
mice
short
term
howev
daili
inject
human
rbc
nsg
mice
lead
high
circul
level
human
rbc
support
erythrocyt
portion
p
falciparum
life
cycl
jimenezdiaz
et
al
engraft
human
rbc
also
enhanc
inject
clodronateload
liposom
kill
host
macrophag
arnold
et
al
use
daili
inject
rbc
human
hepatocyteengraft
mice
would
permit
erythrocyt
hepatocytedepend
part
p
falciparum
life
cycl
human
mice
occur
open
investig
infecti
agent
target
hematopoiet
origin
cell
macrophag
lymphocyt
rbc
exampl
mani
infecti
agent
target
stromal
cell
exampl
n
meningitidi
target
human
nasopharyng
epitheli
cell
stephen
farley
adapt
human
mice
studi
n
meningitidi
use
engraft
human
skin
onto
immunodefici
mice
use
model
studi
pathogenesi
local
vascular
damag
develop
purpura
melican
et
al
anoth
approach
may
engraft
human
nasal
polyp
bernstein
et
al
would
provid
prefer
natur
cell
nich
organ
similar
approach
may
also
use
studi
humanspecif
agent
n
gonorrhoea
target
nich
prefer
urogenit
tract
hill
et
al
addit
human
cytomegaloviru
infect
human
endotheli
cell
human
mous
model
cmv
infect
establish
transplant
human
cmvinfect
intern
mammari
arteri
null
null
mice
engraft
hlamatch
pbl
abeleohl
et
al
human
pbl
infiltr
graft
creat
vascular
lesion
similar
pathogenesi
observ
transplant
arteriosclerosi
human
mous
model
also
need
studi
virus
jc
viru
jcv
polyomaviru
caus
progress
multifoc
leukoencephalopathi
pml
tan
koralnik
jcv
highli
speciesspecif
viru
activ
replic
permiss
human
host
initi
site
infect
may
tonsil
tonsil
materi
human
engraft
human
mice
serv
site
infect
viru
duchos
et
al
yamanaka
et
al
vallet
et
al
gastrointestin
tract
also
serv
site
infect
human
intestin
transplant
human
mice
could
potenti
develop
buisin
et
al
concern
fda
issu
warn
pml
jcv
infect
may
associ
four
commonli
use
drug
rituxan
natalizumab
tysabri
last
resort
medicin
sever
case
multipl
sclerosi
efalizumab
raptiva
brentuximab
vedotin
understand
activ
pathogenesi
jcv
high
prioriti
permit
use
drug
therapi
toward
goal
develop
blt
human
mous
model
permit
evalu
jc
virusspecif
human
immun
respons
may
import
understand
human
immun
system
respond
viru
tan
et
al
emerg
infecti
agent
threat
middl
east
respiratori
syndrom
coronaviru
merscov
http
viru
tropism
noncili
bronchial
epitheli
cell
engraft
human
epitheli
tissu
human
skin
immunodefici
mice
racki
et
al
may
possibl
establish
human
mous
model
emerg
diseas
engraft
tissu
human
pulmonari
tissu
peault
et
al
would
provid
human
mous
model
merscov
also
coronavirus
infecti
agent
target
lung
epithelium
infecti
agent
salmonella
cross
intestin
epithelium
intern
macrophag
neutrophil
dendrit
cell
engraft
human
small
intestin
along
human
hematopoiet
stem
cell
immunodefici
mice
buisin
et
al
may
repres
novel
approach
studi
infecti
agent
human
mice
interest
approach
close
recapitul
pathogenesi
viru
infect
modifi
way
infecti
agent
deliv
studi
dengu
viru
nsg
mice
engraft
cord
bloodderiv
hsc
dengu
infect
aed
aegypti
mosquito
allow
bite
hscengraft
mice
infect
mice
exhibit
higher
sustain
viremia
erythema
thrombocytopenia
mice
infect
direct
intraderm
inject
cox
et
al
use
model
permit
factor
increas
virul
follow
mosquito
bite
includ
potenti
factor
saliva
infect
mosquito
investig
mycobacterium
tuberculosi
tb
infect
million
peopl
annual
kill
million
peopl
tuberculosi
fact
sheet
world
health
organ
geneva
switzerland
http
wwwwhointtbpublicationsglobalreporten
increas
understand
human
immun
respons
tb
infect
critic
develop
effect
vaccin
adapt
human
immun
respons
tb
recent
demonstr
mice
follow
intraven
infect
bcg
use
blt
engraft
model
studi
use
blt
engraft
nsg
mice
infect
intranas
strain
tb
express
red
tomato
fluorophor
demonstr
develop
organ
granulomat
lesion
patholog
chang
reminisc
human
tb
infect
calderon
et
al
human
mice
also
use
studi
infecti
agent
classifi
ebola
viru
caus
sever
hemorrhag
fever
human
lethal
rate
world
health
organ
fact
sheet
http
wwwwhointmediacentr
human
lymphocyt
undergo
apoptosi
ebola
viru
infect
use
nsg
hupbl
model
found
human
lymphocyt
underw
apoptosi
infect
mous
adapt
ebola
viru
infect
wildtyp
ebola
viru
bradfut
et
al
suggest
pathogenesi
ebola
infect
studi
human
mice
clearli
cell
tissu
tropism
identifi
exist
newli
emerg
humanspecif
infecti
agent
new
human
mous
model
engraft
appropri
target
tissu
need
develop
goal
howev
engraft
target
cell
tissu
presenc
autolog
human
immun
system
fig
develop
technolog
gener
human
induc
pluripot
stem
ip
cell
romano
et
al
bayart
cohenhaguenau
may
becom
futur
realiti
exampl
human
hepatocyt
gener
human
ip
cell
yoshida
et
al
medin
et
al
yanagida
et
al
howev
current
effort
gener
function
human
hsc
ip
cell
gener
complet
human
hematopoiet
immun
system
immunodefici
mice
date
success
klump
et
al
howev
progress
continu
identifi
final
step
vitro
differenti
requir
success
gener
true
hsc
human
ip
cell
establish
major
step
forward
human
approach
approxim
decad
ago
genet
engin
revolut
began
base
design
dna
nucleas
capabl
high
effici
precis
modif
genom
lloyd
et
al
porteu
carrol
last
year
develop
target
nucleas
acceler
becom
domin
biotechnolog
advanc
earli
centuri
use
zinc
finger
nucleas
zfn
becam
possibl
target
modifi
genom
directli
mammalian
oocyt
carberi
et
al
cui
et
al
concept
capabl
genet
target
modifi
almost
region
genom
rapidli
engend
develop
transcript
activatorlik
effector
nucleas
talen
technolog
moscou
bogdanov
boch
et
al
hockemey
et
al
develop
crispr
cluster
regularli
interspac
short
palindrom
repeat
technolog
jinek
et
al
wang
et
al
tool
allow
exquisit
effici
manipul
genom
gaj
et
al
briefli
outlin
basic
common
uniqu
aspect
approach
capabl
creat
improv
human
mous
model
tabl
common
key
advanc
approach
effici
precis
target
almost
genom
region
base
dna
sequenc
fig
effici
risen
level
use
embryon
stem
cell
esc
intermedi
creat
precis
genet
modif
mice
gener
longer
necessari
modif
done
directli
fertil
oocyt
carberi
et
al
indic
fig
modif
includ
delet
target
region
lower
frequenc
target
integr
novel
sequenc
region
eg
one
base
frtcre
site
whole
gene
gaj
et
al
crucial
avoid
use
esc
process
execut
mous
strainbackground
precis
fit
experiment
design
need
allow
rapid
direct
sequenti
modif
previous
modifi
character
mous
strain
thu
build
past
anim
model
data
approach
facilit
rapid
develop
adopt
commun
result
genet
modifi
mous
line
exampl
use
approach
nod
nrg
nsg
strain
directli
oocyt
greatli
speed
advanc
use
human
xenotransplant
unpublish
observ
gener
approach
outlin
fig
involv
introduc
fertil
oocyt
protein
commonli
mrna
encod
zfn
talen
target
genom
region
interest
crispr
mrna
encod
plu
signal
guid
rna
sgrna
design
complex
protein
guid
specifi
target
carberi
et
al
hockemey
et
al
jinek
et
al
key
challeng
use
approach
achiev
reproduc
high
effici
desir
genet
modif
especi
relev
modif
requir
knockin
effici
correct
integr
event
lower
nonhomolog
end
join
nhej
event
use
fertil
oocyt
start
materi
effici
correct
target
modif
fall
cost
make
modifi
anim
becom
prohibit
due
number
oocyt
donor
requir
zfn
talen
crispr
avail
commerci
vendor
variou
format
restrict
howev
talen
especi
crispr
construct
standard
molecular
lab
assist
talen
crispr
construct
design
found
web
number
comput
programssit
exist
eg
http
zifitpartnersorgzifit
http
crisprmitedu
mani
genet
element
requir
build
talen
crispr
nucleas
avail
via
http
wwwaddgeneorg
although
system
moder
simpl
molecular
lab
plu
microinject
group
establish
new
technolog
also
engend
host
new
challeng
tabl
rang
difficulti
make
high
qualiti
mrna
abil
microinject
especi
pronuclear
inject
requir
screen
correct
event
founder
anim
exampl
common
unexpect
occurr
other
report
often
founder
anim
somat
germ
line
gamet
mosaic
thought
due
nucleas
activ
occur
post
one
cell
oocyt
stage
exampl
even
cell
stage
blastomer
independ
genet
modif
event
result
anim
event
often
mosaic
possibl
quit
differ
independ
genet
modif
event
lead
identif
founder
correct
event
tail
deriv
dna
upon
breed
produc
offspr
perhap
whole
seri
differ
genet
modif
ie
tail
deriv
dna
alway
gamet
sung
et
al
howev
approach
matur
actual
mechan
involv
nucleas
medit
homolog
recombin
fulli
understood
expect
modif
event
rise
somat
germ
cell
issu
often
rais
use
nucleas
modif
possibl
offtarget
damag
genom
caus
lack
specif
sander
et
al
yang
et
al
valid
concern
especi
case
crispr
recognit
site
nucleotid
degre
nonspecif
wobbl
end
detect
fu
et
al
hsu
et
al
pattanayak
et
al
howev
challeng
view
context
previou
genet
engin
approach
base
esc
random
transgenesi
immun
collater
genom
damag
adag
buyer
bewar
relev
strongli
encourag
good
breed
record
maintain
untoward
effect
seen
examin
potenti
offtarget
effect
elimin
rare
confirm
although
focus
genet
modif
human
mice
approach
also
use
dna
organ
embryon
stage
germ
cell
access
rang
maiz
shukla
et
al
parasit
protozoan
malaria
smidler
et
al
rat
mashimo
et
al
human
urnov
et
al
open
whole
vista
possibl
develop
human
anim
model
human
mice
rapidli
becom
import
tool
studi
humanspecif
infecti
agent
model
mani
human
agent
avail
studi
pathogenesi
infecti
agent
evalu
drug
efficaci
develop
test
vaccin
howev
remain
opportun
optim
immunodefici
host
increas
robust
engraft
human
immun
system
identifi
novel
model
engraft
nonhematopoiet
human
cell
tissu
target
infecti
agent
implement
novel
technolog
rapidli
gener
new
genet
modifi
host
target
nucleas
base
genet
engin
greatli
speed
develop
allow
rapid
sequenti
modif
preexist
establish
strain
use
human
mice
small
anim
model
studi
humanspecif
agent
like
provid
novel
insight
biolog
agent
might
otherwis
avail
antigenpres
cell
nsg
mice
provid
power
platform
engraft
human
cell
tissu
limit
develop
function
certain
lineag
human
cell
overcom
transgen
express
human
hla
molecul
cytokin
speciesspecif
factor
target
mous
gene
elimin
host
mhc
antigen
gene
reduc
innat
immun
nsg
mice
recent
develop
nsgbase
model
support
engraft
multipl
type
human
cell
tissu
engraft
human
cell
support
infect
mani
differ
human
pathogen
simpl
schemat
represent
zfn
talen
crispr
mode
action
start
genom
dna
target
sequenc
nucleas
introduc
cell
oocyt
left
zfn
talen
compos
pair
protein
design
bind
defin
base
unit
also
carri
oblig
homo
heterodim
foki
nucleas
upon
dimer
lead
doubl
strand
cut
dscut
interven
dna
spacer
sequenc
right
protein
caus
doubl
strand
break
target
site
complex
signal
guid
rna
sgrna
defin
target
sequenc
plu
trinucleotid
protospac
adjac
motif
pam
recogn
upon
doubl
strand
dna
break
occur
repair
process
initi
lead
absenc
homolog
dna
nonhomologu
endjoin
nhej
repair
delet
one
mani
hundr
base
ie
target
delet
mutat
presenc
dna
homolog
target
cut
site
homolog
recombin
homolog
direct
repair
hdr
occur
provid
precis
dnagen
sequenc
integr
gaj
et
al
orlando
et
al
nhej
hdr
highli
success
mous
direct
oocyt
multipl
background
although
time
write
frequenc
homolog
recombin
gener
less
nhej
gaj
et
al
low
et
al
yang
et
al
sequenc
event
gene
modif
use
target
nucleas
zfn
talen
introduc
fertil
oocyt
gener
mrna
encod
bind
site
nucleas
zfn
talen
crispr
nucleas
signalguid
rna
sgrna
b
microinject
oocyt
introduc
pseudopregn
host
femal
carri
term
c
result
offspr
screen
desir
genet
modif
event
gener
pcr
sequenc
mice
carri
desir
modif
event
bred
ensur
germlin
transmiss
elimin
possibl
mosaic
